Filing Details
- Accession Number:
- 0001140361-24-014226
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-03-19 21:48:01
- Reporting Period:
- 2024-03-18
- Accepted Time:
- 2024-03-19 21:48:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1368514 | Adma Biologics Inc. | ADMA | () | 4 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1250195 | Steve Elms | 489 5Th Avenue 10Th Floor New York NY 10017 | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2024-03-18 | 49,887 | $6.01 | 2,527,500 | No | 4 | S | Indirect | See footnote |
Common Stock | Disposition | 2024-03-19 | 411,829 | $6.08 | 2,115,671 | No | 4 | S | Indirect | See footnote |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | See footnote |
No | 4 | S | Indirect | See footnote |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 76,441 | Direct |
Footnotes
- These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10 year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon.
- The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.02. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.17. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- Includes, as of the transaction date, (i) 24,040 restricted stock units ("RSUs") granted on February 26, 2024 and reported on this Form 4, that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date; and (ii) 52,401 shares of common stock owned by the reporting person.